NCT04896073View on ClinicalTrials.gov

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Adenosquamous Carcinoma of the Pancreas
Interventions
DRUG

Minnelide

Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.

DIAGNOSTIC_TEST

ECG

Screening and end of treatment visit.

DIAGNOSTIC_TEST

CT/MRI

Screening. Subsequent cycles Day 1 (≤3days) and Day 15 (±2 days) (every other cycle). End of treatment visit.

PROCEDURE

Tumor Biopsy

Optional. Baseline Cycle 1, Day 1 and Cycle 1, Day 15. End of treatment visit or progressive disease.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH